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EVALUATING THE CONCORDANCE OF N-TERMINAL AND FULL LENGTH 
HUNTINGTON’S DISEASE MODIFIERS AND IDENTIFYING POTENTIAL 
THERAPEUTIC TARGETS IN DROSOPHILA 
BENJAMIN BLEIBERG 
ABSTRACT 
  
 Huntington’s disease (HD) is one of nine polyglutamine diseases and it is caused 
by a CAG expansion in the HTT gene. HD is an autosomal, dominantly inherited 
neurodegenerative disease affecting between 2 and 5 individuals per 100,000 worldwide 
and it is currently untreatable. HD spreads from the striatum to the rest of the brain and 
causes widespread motor, cognitive, and psychiatric symptoms, including Huntington’s 
chorea.  
 A fruitful approach to identifying potential therapeutic targets for HD is to modify 
genes in a model organism in an unbiased manner and screen the effect by testing the 
model in a functional assay. Drosophila models of HD have emerged as key tools for 
these large scale genetic screens thanks to their combination of ease of maintenance, and 
breeding in large numbers and their ability to be tested neurobehaviorally. 
 During the course of HD pathogenesis in mammals, the FL-HTT protein is 
cleaved by many proteases including caspase-6. This cleavage leads to the co-existence 
of N-terminal (NT) as well as full-length (FL) forms of mutant HTT in the HD neurons. 
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Drosophila lacks caspase-6 therefore FL-HTT is not naturally cleaved at its target site, 
this allows us to express either the FL mutant HTT or its cleaved NT fragment 
independently to characterize their differential pathogenic contribution. 
 This study aims to test the concordance of a sample of 75 NT-HTT modifiers 
identified through a directed screen by testing them in a FL-HTT model. In doing so, we 
hope to identify shared modifiers and shared functional genetic networks, which may be 
particularly central to HD progression and useful areas in which to discover therapeutic 
targets. Further, this study may help to determine what types of models are necessary for 
future screens to adequately understand the genetic networks that underpin HD 
progression. 
 In order to assess the impact of the modifier, flies expressing both the modifier 
and FL-HTT were tested in a climbing assay that measures motor function taking 
advantage of the model’s innate negative geotactic behavior. Motor performance is 
measured as the percentage of flies of each genotype that climb up to a 9 cm threshold in 
a given time interval. Flies were tested at 6 time points on days 18, 19, 20, 21, 22, and 25 
of age in order to observe their level of neurobehavioral function in comparison to a 
positive control of flies with FL-HTT and no modifier and a negative control of flies 
without mutant HTT. 
 When NT modifiers were tested in the FL model, there was an enrichment in 
modifiers relative to what is seen by chance. The NT suppressor sample was significantly 
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enriched in modifier genes that effected motor performance in the FL model. Meanwhile, 
NT HD enhancers were not enriched with modifiers in the FL model. Some modifiers 
demonstrated contradictory effects on motor performance depending on the HD model 
tested. This could be caused by different mechanisms of toxicity inherent to NT versus 
FL HD or from secondary toxicity as the FL experiment occurred over a longer time 
period and flies were aged at a higher temperature.  
 There was particular enrichment of modifiers in the calcium signaling and 
inflammation and cytoskeleton stress response pathways, which are robust functional 
gene networks identified by previous gene screening. These findings suggest that these 
shared networks are particularly central to HD progression and both are involved in 
inhibiting a cell’s ability to cope with stress and promoting excitotoxicity. The 
aforementioned pathogenic features are associated with impaired autophagy, which many 
see as the key to HTT clearance and ultimately rescuing neurons from degradation and 
curing HD.  
 As genetic screening continues in Drosophila, shared networks between models 
have the potential to reveal new therapeutic targets and broaden our understanding of the 
mechanisms that lead to HD progression. These lessons will be essential as whole 
genome unbiased screenings in Drosophila continue and our networks become more 
robust and interconnected. Despite the enrichment in shared modifiers, our results show 
not infrequent contradictory effects on motor performance when NT modifiers are tested 
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in the FL model. As such, we suggest that future screens test both FL and NT models 
independently to best study the causes of HD and to help identify the shared modifiers 
and networks, which are promising areas to mine for therapeutic targets. 
!  viii
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INTRODUCTION 
Huntington’s Disease Epidemiology and Background  
 Huntington’s Disease (HD) is a dominantly inherited autosomal disease for which 
onset of symptoms usually begins between age 30-50 and progresses slowly over the 
course of 10-15 years. However, patients have become symptomatic as early as age 2 and 
as late as age 80 with 10% showing symptoms before age 20 (Zuccato, Valenza, & 
Cattaneo, 2010). The disease is terminal as there are no current cures for the toxic gain of 
function and death tends to occur between 10-15 years after symptom onset (Orr & 
Zoghbi, 2007). HD is one of nine polyglutamine diseases caused by a CAG expansion of 
the HTT gene on chromosome 4, discovered in 1993, which leads to a polyglutamine- 
expanded translated mutant HTT protein. (Gatchel & Zoghbi, 2005; Imarisio et al., 2008). 
Pathology is triggered when the expanded polyglutamine stretch exceeds 36 CAG 
repeats, but longer expansions, up to 121 repeats are associated with earlier and more 
rapid disease progression (Lu et al., 2013; Orr & Zoghbi, 2007).  
 HD is a debilitating neurodegenerative disease, which effects 5.7 per 100,000 
people in Europe, North America, and Australia and 2.7 per 100,000 people worldwide 
(Pringsheim et. al, 2012). This geographic distribution can be explained by larger average 
CAG tract sizes, a higher preponderance of less stable HTT gene haplotypes in the 
population, and better diagnostic and reporting information in the 3 continents with 
higher reported rates of HD (Pringsheim et. al, 2012). In the US alone 30,000 people are 
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affected and 200,000 people are at risk of developing the disease later in life, as children 
of a parent with HD have a 50% chance of developing the disease over their lifespan 
(Rawlins, 2010). Although Dr. George Huntington first described the disease in 1872, 
there is no known cure, and at present people diagnosed with the autosomal dominant 
disorder invariably lose their independence, often at a relatively young age, as their motor 
dysfunction and dementia become gradually more severe. Ultimately HD patients tend to 
die young, succumbing to one of the disease’s co-morbidities (Zuccato, Valenza, & 
Cattaneo, 2010). 
HD Pathology and Symptomatology  
 HD patients suffer from a wide range of motor, cognitive and psychiatric  
symptoms as neurodegeneration and dysfunction spread from the striatum, to the rest of 
the brain. Medium sized spiny striatal neurons containing GABA are most susceptible to 
HD related degeneration and tend to be the first neuronal population impacted (Orr & 
Zoghbi, 2007). The earliest manifestations of HD are often progressive weight loss, 
hypokinesia, alterations in sexual behavior, and disturbances in circadian rhythm, but 
chorea is the most pronounced symptom (Heemskerk & Roos 2012; Walker, 2007; 
Zuccato, Valenza, & Cattaneo, 2010). Cognitive symptoms of HD include difficulty with 
speech and challenges processing and organizing information. Psychiatric symptoms are 
associated with stark personality changes, which can include: depression, aggression, 
social withdrawal, anxiety, irritability, apathy, and OCD (Walker, 2007). These motor, 
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cognitive, and psychiatric symptoms reflect the areas of the brain affected by HD. For 
example, the initial degeneration in the striatum of the basal ganglia seen in Figure 1 
disrupts control of voluntary motor movements, which leads to Huntington’s chorea (Han 
et al., 2010). In humans HD progression inevitably leads to death, frequently from 
pneumonia and heart disease, but also due to falls, nutritional deficiencies, or 
cerebrovascular disorders (Lanska, Lavine, Lanska, & Schoenberg, 1988; Zuccato, 
Valenza, & Cattaneo, 2010). A recent analysis of the cause of death of HD patients in a 
large, representative sample attributed 86.8% of the deaths to aspiration pneumonia due 
to dysphagia (Heemskerk & Roos, 2012). 
Figure 1. MRI visualization of HD pathology.  
MRI images contrast the Striatum and Cortex of a normal individual and an HD patient. 
HD causes severe neuronal loss in the Caudate and Putamen (Striatum). This is illustrated 
by the severe loss of axons and the swelling of the lateral ventricles in B as compared to 
A. With time degeneration affects other brain regions, as seen in the thinning of the 
cortical grey matter in B compared to A. Adapted from Fennema-Notestine et al., 2004. 
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 Research has sought to map HD progression and the precise mechanisms that 
confer its neurodegenerative effect. Experiments in cells have determined that these CAG 
coding repeat sequences are intrinsically toxic and are the root cause of HD early 
mortality (Marsh et al., 2000). Disease pathogenesis is caused by accumulations of 
mutant HTT protein in the cytoplasm and the nucleus of neurons and glia (Marsh, 2003; 
Yamamoto, Cremona, & Rothman, 2006). Recent research suggests that the cleavage of 
mutant HTT specifically by caspase-6 at amino acid 586 and the subsequent 
accumulation of cleavage fragments is necessary for neurodegeneration (Graham et al., 
2006; Warby et al., 2008).  
 The NT fragment of mutant HTT is largely composed of the polyglutamine 
expansion and is able to accumulate in both the nucleus and cytoplasm, while mutant  
FL-HTT protein accumulates primarily in the cytoplasm, both are shown in Figure 2 
(Warby et al., 2008). While some theories suggest caspase activation is the key element to 
disease progression, other models emphasize decreased proteosome activity, increased 
production of reactive oxygen species and dysregulation in transcription and 
mitochondrial function. The literature remains unsettled as to which of these molecular 
mechanisms of neural degeneration is most important to disease progression, but all 
likely contribute in varying degrees (Imarisio et al., 2008; Rubinsztein & Carmichael, 
2003; Steffan et al., 2001; Williams et al., 2008). 
!4
Figure 2. Comparing normal and pathogenic Huntington’s proteins in Drosophila.  
(A) shows wild type HTT protein (B) The polyglutamine sequence within the HTT gene 
is expanded in HD, resulting in the production of abnormally elongated polyglutamine 
tract (polyQ tract). HD induces the production of longer mutant FL-HTT protein, which 
in humans and mouse models is then cleaved by proteases like caspase-6 into smaller NT 
fragments (C) that translocate into nuclei of neurons. Since Drosophila lack caspase-6 
there are two Drosophila models of HD, expressing in the CNS either the FL (B) or 
mutant NT-HTT (C), to mimic these two components of the disease. 
Normal HTT protein is involved in transcriptional regulation, vesicle trafficking, the 
regulation of the actin cytoskeleton stress response, and axonal transport. As such, mutant 
HTT disrupts these processes and can also spread through the synapses and axons of 
neurons (Munsie et al., 2011). These protein accumulations are thought to lead to 
neuronal dysfunction and death possibly through excitotoxicity and are also implicated in 
the development of a range of primary motor symptoms of HD in model organisms and 
humans including chorea, spasms, tics, falls (Graham et al., 2006; Zuccato, Valenza, & 
Cattaneo, 2010).  
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(A) Normal HTT 
(B) FL-HTT in 
HD 
(C) NT-HTT in 
HD
Studying Neurodegeneration in Model Organisms 
 Animal models have been crucial in illuminating the mechanisms behind HD  
pathogenesis. Studies on model organisms have linked mutant HTT protein to 
dysregulations of autophagy, mitochondrial function, axonal transport, and synaptic 
transmission (Munsie et al., 2011; Zoghbi & Botas, 2002). Research has uncovered the 
potential of Drosophila melanogaster as a key animal model for better understanding HD 
progression and identifying potential therapeutic targets (Muqit & Feany, 2002). 
Drosophila lacks caspase-6; therefore FL-HTT is not cleaved at this site in flies. As a 
result, Drosophila models have the added advantage of allowing for the differential and 
independent induction of NT and FL HD pathologies. This allows for greater ease of 
elucidating the genetic interactions that play a role in HD progression. Further, 
Drosophila have a well-established model of inducing gene expression through the 
GAL4/UAS system shown in Figure 4, which allows for the targeted expression of genes 
of interest in neurons, glia, retina, and other relevant populations of cells (Brand & 
Perrimon, 1993; Marsh, 2003).  
 Thanks to their short generation time, rapidly growing populations, low cost to 
maintain, and well characterized genome, flies have emerged as an important model 
organism for unbiased genome screenings. D. melanogaster has been used as an 
experimental model organism since the landmark experiments on heredity by Thomas 
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Hunt Morgan in the 1900’s, but later research has shown the remarkable interrelatedness 
of human and fly genetics (Muqit & Feany, 2002). Drosophila models have over 50% 
gene conservation with humans and the same basic neuronal physiology and 
neurotransmitters (Dopamine, Acetylcholine, GABA, Glutamate) as mammals. Further, 
75% of the genes associated with disease in humans have an identified homolog in flies 
(Pandey & Nichols, 2011). Thanks to the identification of genetic mutations that are the 
putative cause of neurodegenerative diseases like HD and the autosomally dominant 
nature of the genetic inheritance of the disease, it is possible to generate lineages of D. 
melanogaster that model HD (Marsh et al., 2000). 
 While genetic screens are capable of identifying certain changes in gene 
expression associated with a particular disease, they become much more powerful 
research tools when tied to a functional assay. Functional assays allow researchers to 
determine if the changes in gene expression observed molecularly by microarrays or 
RNAseq are compensatory (beneficial) or pathogenic (deleterious). Fortunately, 
Drosophila exhibit a range of characteristic, repeated measurable behaviors, which allow 
for behavioral assays of neuronal function on a given genetic lineage (Marsh & 
Thompson, 2004; Pandey & Nichols, 2011). Behavioral assays provide researchers with 
an opportunity to test for nervous system dysfunction and to identify systemic 
compensatory mechanisms used by neurons to slow HD progression and neuronal death. 
Drosophila thanks to their functional nervous system, quantifiable behavior, and ease to 
cross and maintain are an ideal model organism in which to complete a large scale 
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genetic screen incorporating a functional assay to uncover compensatory and pathogenic 
networks of transcriptomic alterations in HD (Muqit & Feany, 2002; Zoghbi & Botas, 
2002).  
Specific Aims  
 While many researchers have studied neurodegenerative disease in Drosophila 
models there are few investigations dedicated to the potential overlap of findings based 
on the type of HD model used (Marsh et al., 2009; Zoghbi & Botas, 2002). There remains 
a need to settle this issue as a significant amount of work remains to be done to complete 
genome wide screening and HD remains as yet incurable. As such, it is important to 
understand which models best represent HD pathology in humans as genome wide 
screens continue. Further, one method of finding especially promising therapeutic targets 
is to identify modifier genes, which suppress disease pathology across different models 
and screen the networks in which they participate, which may help to find the keys to 
treating HD.  
 Our research team hypothesizes that the concordance of NT modifiers in the FL 
model will be significant, but not complete. As such, testing NT modifiers in the FL 
model should show a significant enrichment in modifiers relative to what is seen when 
testing genes in an unbiased fashion. However, because of the different mechanisms of 
neural degeneration and areas of localization for both HD model types, we expect that the 
concordance will be far from perfect. If this hypothesis is supported, then the best way to 
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understand the functional gene networks that underpin HD in future genetic screens will 
require testing both NT and FL models of the disease in Drosophila independently.  
 We also hypothesize that genes that appear to be modifiers in both the NT and FL 
models of HD are especially central to HD pathology. These genes and the shared 
networks to which they belong may be particularly useful to mine for potential 
therapeutic targets. Lastly, we hypothesize that modifiers that are part of a robust 
functional gene network such as those shown in Figure 3 are more likely to be shared 
between FL and NT HD models, but that there should be no statistically significant 
difference in the enrichment of shared modifiers between similarly robust pathogenic and 
compensatory gene networks. The overall aims of this project are to: 
1. Identify the amount of overlap between modifiers in NT and FL models of HD in 
Drosophila and highlight modifiers that are shared between both models as therapeutic 
targets of interest 
2. Analyze which NT functional networks, compensatory or pathogenic, show 
enrichment in the FL model 
3. Determine if the concordance of modifiers between the models is strong enough that 
unbiased genetic screening can be completed with only one of either the FL or NT 
models 
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Figure 3. Schematic of calcium signaling and actin cytoskeleton regulation and 
NFKB functional genetic pathways.  
Panel A shows the distribution of modifiers in the greater compensatory network showing 
18% are related to the calcium signaling pathway. Panel B depicts the human genes 
involved in the calcium signaling pathway and how they are related. The top rows of 
Panels C and D show expression levels of the human genes in the caudate nucleus of 
controls and HD patients. The bottom rows of Panels C and D show the motor 
performance graphs of Drosophila models with varying gene modifications to a sample 
of genes involved in the calcium signaling pathway. Panel E shows the same information 
as C and D, but in the context of genes involved in the primarily pathogenic actin 
cytoskeleton regulation and NFKB pathway. Panel F depicts this pathway and the 
functional relationships between genes involved in cytoskeletal regulation and 
inflammation. Adapted from Al-Ramahi et. al, 2016. 
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METHODS 
Sample 
 Drosophila melanogaster strains were ordered from the Bloomington Drosophila 
Stock Center at Indiana University and the Vienna Drosophila Resource Center (VDRC) 
with shRNA knockdowns of the entire Drosophila transcriptome. The genotypes tested 
consisted of modifiers identified by a forward genetic screen of NT HD models. Each of 
these modifiers had at least one human ortholog identified by P-BLAST analysis on 
Flybase with a cutoff at BLAST e-value=1E-10. The total sample of NT modifiers was 
comprised of 104 genotypes with 352 human orthologs.  
 In order to maintain the expression of the unstable shRNA throughout the lifespan 
of the fly, researchers utilize the well-established GAL4/UAS system shown in Figure 4 
(Brand & Perrimon, 1993). This system involves crossing a driver line of males with the 
transcription factor GAL4 with females whose genome contains a promoter, the 
Upstream Activating Sequence (UAS) associated with a gene that is turned off. After this 
cross, the progeny possess the GAL4 transcription factor bound to the UAS. This 
combination enables transcription and translation and ultimately the generation of a 
protein product from the gene associated with the UAS. This allows for the over 
expression of mammalian or Drosophila genes or a loss of function with hairpinRNA, 
miRNA, or a dominant negative (Brand & Perrimon, 1993).  
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 The UAS can be associated with wide variety of cell types ranging from the CNS 
to specific neurons, muscle cells, eye cells, photoreceptors, mechanoreceptors, and glia 
depending on the type of phenotype the researcher is attempting to induce and the assay 
utilized (Marsh & Thompson, 2004). In this experiment, the neuronal driver used was 
Elav-GAL4, which drives expression pan-neuronally (Robinow & White, 1991). 
Figure 4: The GAL4/UAS expression system in Drosophila.  
The GAL4 transcription activator binds to UAS sites. The GAL4 driver line expressing 
the transcriptional activator, is crossed with a different line carrying the UAS transgene, 
which is responsible for the expression of a specific coding sequence. In the absence of 
either of the components, the specific gene is not expressed in a specific tissue, making 
tissue specific transgene expression ineffective. Adapted from Brand & Perrimon, 1993. 
We use the system to manipulate the expression of NT (UAS-NT-HTT[128Q] or FL 
(UAS-FL-HTT[200Q] mutant HTT in the central nervous system. The number preceding 
Q signifies the number polyglutmaine repeats present in the mutant HTT protein. 
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Crosses 
  The 104 selected genotypes representing modifiers of NT HD progression 
identified from the initial screen were amplified in large bottles with yeast to accelerate 
population growth. The addition of yeast is important as it increases the reproductive 
output and sexual receptivity of the female flies (Gorter et al., 2016). 20 virgin females 
were collected and divided evenly into 2 vials for each gene modification model of 
interest. Each vial of 10 virgin females with the UAS was crossed with 4 male flies that 
expressed FL HD and the GAL4 transcription factor. After 3 days, once all of the females 
have mated, crosses were transferred into bottles with yeast allowing for females actively 
expressing the shRNA to produce many offspring with FL HD males. Parents of the cross 
were then removed from the bottle after 5 days at 25°C and all older progeny were 
removed after 5 days at 29.5°C. This second removal step was needed to establish a time 
zero in which all flies collected from the bottle for behavioral testing on the following 
day would have emerged from their pupae within a 24-hour window and therefore were 
the same age.   
 After this step, 30 females with all of the following: the expressed shRNA, FL 
HD, and the UAS bound with the elav-GAL4 neuronal driver were selected the following 
day. Female flies with all of these traits were selected by sorting them out of a 
background population of flies with 3rd chromosome linked balancers TM3, TM6B, and 
SM5, which each have distinct phenotypes. TM3 positive flies exhibit a stubble hair 
phenotype; TM6B positive flies display a darker, shorter, stouter phenotype with 
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disorganized bristles on their humerus, referred to as ebony, tubby, and humeral 
respectively; SM5 positive flies have curly wings.  
 The same protocol used to collect and age the flies from the initial NT screen was 
used for the FL HD models tested in this experiment. However, since the NT model has 
shown more toxicity than the FL model, FL flies are aged 18 days before testing, while 
NT models are only aged 8 days before their first test. For the same reason, FL animals 
are incubated at a slightly higher temperature, 29.5°C as opposed to 28.5°C. This 
temperature difference is based on the fact that the GAL4-UAS system is temperature 
sensitive with higher temperatures driving gene expression more (Marsh & Thompson, 
2004). Females are selected so as to circumvent the dosage compensation problem of 
using the elav driver, which is on the X chromosome. Fly females unlike humans express 
both X chromosomes while males increase the expression of their single X chromosome. 
As such, males with the elav driver would overexpress it to compensate for their single X 
chromosome (Zaharieva, Haussmann, Bräuer, & Soller, 2015). Crosses, shown in table 1, 
were made between female virgin Drosophila carrying a UAS-shRNA transgene and 
males carrying mutant FL-HTT (elav-GAL4; UAS-HTTFLQ200). 
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Table 1. Drosophila HD model crossing scheme.  
The table represents the crosses used to generate HD models in Drosophila.  
Demonstrating that the progeny selected for our climbing assay are females positive for 
the UAS, shRNA and HD. 
1)  Cross        ♀ yw;  UAS: shRNAi    X  ♂ ELAVGAL4 ; UAS: HTT/ TM6B 
 
F1 progeny  
2)           ♀ ELAVGAL4/ yw ; UAS: shRNAi/ + ; TM6B/ + 
3)           ♀ ELAVGAL4/ yw ; UAS: shRNAi/ + ; UAS: HTT/+ 
4)           ♂ yw/y ; UAS: shRNAi/ + ; TM6B/ + 
5)           ♂ yw/y ; UAS: shRNAi/ + ; UAS: HTT/+ 
Materials: Measure of Climbing Phenotype 
 In order to measure the neurobehavioral effect of NT modifiers of HD in the FL 
HD model, the 30 females of each genotype collected from each cross were divided into a 
test group of 15 flies and a backup group of 15 flies and then aged for 18 days at 29.5°C. 
At day 18, the flies were tested in a behavioral climbing assay, which takes advantage of 
the flies’ innate negative geotactic behavior when tapped to the bottom of a climbing tube 
(Gargano, Martin, Bhandari, & Grotewiel, 2005). The assay involves transferring the 
aged flies of each separate genotype from their aging tubes to longer climbing tubes seen 
in Figure 5 panel B and counting them to ensure 15 flies of each genotype are present in 
each tube. 
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Figure 5: Drosophila climbing data acquisition system of the Botas lab.  
(A) This system was used to measure the number of flies that climb above 9 cm in 16 
seconds for NT or 24 seconds for FL HD Drosophila models. 15 flies are placed in 
separate tubes (arrowheads) and three infrared detectors measure the flies’ climbing 
abilities simultaneously (double head arrows). (B) The tubes are tapped at timed 
intervals, causing the flies to fall to the bottom of the tube and producing the negative 
geotactic response. As the flies climb above 9 cm in the tubes, they pass an infrared beam 
detector which reports to the computer the percent of flies of each genotype that reach the 
threshold. 
 The flies are then “woken up” by shaking them in a rack of tubes 10 times in 
order to overcome a “warm-up” or increasing climbing speed quantifiable in the first 10 
climbing attempts that plateaus after these 10 climbings. The climbing tubes are then 
placed in a rig allowing an operator to shake 10 tubes simultaneously. The entire rig, as 
seen in Figure 5, is lifted up then brought down, taking care to ensure the flies are at the 
bottom of the tube after this interval and then 24 seconds are set aside for the flies to 
climb up the tubes before shaking is repeated and they are knocked to the bottom of the 
tube again. This shaking step is repeated a total of 10 times and after each shaking, the FL 
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HD model flies are given another 24 seconds to climb and the number of flies of each 
genotype that reach the 9 cm high infrared beam on the tubes is recorded.  
 Data is released in the format of mean percentage of flies in each tube that reach 
the 9 cm infrared reader in each day’s climbing trial by genotype. This assay was 
repeated 6 times at fly ages of 18, 19, 20, 21, 22, and 25 days for this experiment. Dead 
flies or flies lost during transfer were replaced with backup flies from the same cross 
collected on the same day as and aged alongside and in the same conditions as the 
experimental flies of the same genotype. The flies were characterized as suppressors, 
enhancers, or non-modifiers by graphical analysis of their climbing phenotype compared 
to that of a positive control of W1118 x HTTFLQ200HD flies and a negative control of 
W1118 x elav-GAL4 flies as seen in Figure 6. Control group flies were aged and tested in 
the same conditions and at the same time as the experimental flies. The effect on motor 
performance of each genotype tested in the FL model was compared to its effect in the 
NT model as shown in Table 2. The concordance in modifier effect in both models was 
then calculated. Finally, the number and proportion of modifiers, which exhibited the 
same effect on motor performance in both the NT and FL models that were present in the 
calcium signaling pathway and cytoskeleton regulation and NFKB pathway was 
investigated. 
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RESULTS 
 Of the 104 NT modifiers identified through an unbiased partial screen of the 
Drosophila genome, 29 either failed to yield enough flies in amplification to cross or the 
cross failed to yield enough flies to test in the neurobehavioral assay. 75 NT modifiers 
were tested in the FL model through a neurobehavioral climbing assay and 38 (51%) of 
the tested genes were also modifiers in the FL model. As such, 37 (49%) of the NT 
modifiers showed no demonstrable effect in motor performance when tested in the FL 
model. Further, 5 (7%) of the confirmed NT modifiers tested in the FL model died during 
the aging process before the first day of testing. While these 5 genotypes are suspected of 
being enhancers of HD, they will be re-tested to validate their true effect on FL-HTT HD 
progression.  
 Of the 51 NT suppressors tested, 21 (41%) were suppressors, 2 (4%) died while 
aging, 24 (47%) were non-modifiers, and 4 (8%) were enhancers in the FL model.  
 Of the 24 NT enhancers tested, 4 (16%) were enhancers, 3 (13%) died while 
aging, 13 (54%) were non-modifiers, and 4 (16%) were suppressors in the FL model. In 
total 28 of the 75 NT modifiers tested (37%) demonstrated the same type of modification 
in the FL model. Of those shared modifiers, 14 (50%) were members of the 
compensatory genetic network and 14 (50%) belonged to the overall pathogenic network. 
Further, 9 of the shared compensatory modifiers were part of the calcium signaling 
functional network and 7 of the shared pathogenic modifiers were members of the actin 
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cytoskeleton regulation and NFKB pathway. Taken together, 16 of the 27 (59%) 
modifiers that exhibited the same effect in both NT and FL models were part of two 
particularly robust functional gene networks. 
Table 2. NT modifiers effect’s in the FL model.  
Drosophila genes with a protein Blast e-value of 1E-10 or lower that were identified as 
modifiers in the NT HD Drosophila model were tested in the FL HD model and their 
effect on motor performance, type of modification (RNAi, overexpression, or loss of 
function) and human gene to which the Drosophila homolog relates are reported below. E 
signifies an enhancer of HD progression corresponding to decreased motor performance, 
S signifies a suppressor of HD progression related to improved motor performance, = 
signifies a non-modifier. Died means that the experimental flies died while aging and 
may be enhancers, but will be re-amplified and re-tested. A loss of function mutation 
results in the gene’s protein losing its ability to fulfill its normal molecular functions. An 
overexpression modification is one in which a gene produces significantly more of its 
protein product than normal (Prelich, 2012). 
Human/
Mouse 
Gene 
Symbol
Drosophila  
Homologous 
Gene
Transcrip
tomic 
change in 
human
Transcripto
mic change 
in R6-mouse 
model
Class Effect on 
motor 
performance 
in NT model 
Effect on 
motor 
performance 
in FL model
Allele
ARHGAP20 RhoGAP71E DOWN DOWN LOF S  = 12092
ATP8A2 CG42321 DOWN UP LOF S  = 14134
CACNB4 Ca-beta DOWN DOWN LOF S  = 11362
EGR1 sr DOWN DOWN VDRC-RNAi S  = 105282
EGR4 sr DOWN DOWN VDRC-RNAi S  = 105282
GABRA1 CG8916 DOWN DOWN VDRC-RNAi S  = 9138
HRH3 D2R DOWN DOWN VDRC-RNAi S  = 11471
DRD2 D2R DOWN DOWN VDRC-RNAi S  = 11471
HTR2C D2R DOWN UP VDRC-RNAi S  = 11471
HS6ST2 Hs6st DOWN DOWN VDRC-RNAi S  = 110424
KCNMA1 slo DOWN DOWN VDRC-RNAi S  = 6723
LATS2 wts UP DOWN VDRC-RNAi E  = 106174
PACSIN1 Synd DOWN UP OE E  = 17200
PDE7B dnc DOWN DOWN LOF S  = 4714
PLCB1 Plc21C DOWN DOWN RNAi S  = 26557
PLCB1 Plc21C DOWN DOWN RNAi S  = 26558
PPP3CA CanA1 DOWN DOWN VDRC-RNAi S  = 32284
!20
RAB3A Rab3 DOWN UP OE E  = 9764
RGS14 loco DOWN DOWN VDRC-RNAi S  = 9248
ROCK2 rok DOWN DOWN LOF S  = 6665
VDAC1 porin DOWN DOWN LOF S  = 10563
ACTN1 Actn DOWN DOWN VDRC-RNAi E  = 7761
ACTN2 Actn DOWN DOWN VDRC-RNAi E  = 7761
ADCYAP1R1Dh44-R2 UP UP VDRC-RNAi S  = 43314
AGAP3 cenG1A DOWN UP VDRC-RNAi E  = 100123
ARPP19 endos DOWN DOWN VDRC-RNAi E  = 34173
ARPP19 endos DOWN DOWN VDRC-RNAi E  = 106825
BMP2K Nak UP DOWN VDRC-RNAi S  = 35482
CELF4 bru-3 DOWN UP VDRC-RNAi E  = 102442
HSPH1 Hsc70Cb DOWN DOWN LOF E  = 11485
HSPH1 Hsc70Cb DOWN DOWN OE S  = 15035
IDS CG12014 DOWN UP VDRC-RNAi E  = 105970
NDRG3 MESK2 DOWN UP VDRC-RNAi E  = 19536
PDE1B Pde1c DOWN DOWN LOF E  = 11440
PPP1R16B MYPT-75D DOWN DOWN OE S  = 23705
SYN1 Syn DOWN UP OE S  = 17305
CALB1 Cbp53E DOWN DOWN VDRC-RNAi S  S 41812
LIMK2 LIMK1 UP UP VDRC-RNAi S  S 25343
PACSIN1 Synd DOWN UP LOF S = 16776
CRISPLD1 CG8483 UP DOWN VDRC-RNAi E died 108588
ROCK2 rok DOWN DOWN VDRC-RNAi S died 3793
KCNAB1 Hk DOWN DOWN VDRC-RNAi E died 101402
MYST3/KAT6enok UP UP VDRC-RNAi S died 37527
PREPL CG5355 DOWN UP VDRC-RNAi E died 109603
PLK2 polo DOWN DOWN LOF S E 11543
PTBP1 heph UP UP VDRC-RNAi E E 110749
STXBP1 Rop DOWN UP OE E E 27158
AP1S1 AP-1sigma DOWN DOWN VDRC-RNAi E E 107322
ATP2A2 Ca-P60A DOWN DOWN VDRC-RNAi E E 107446
HSPB1 l(2)efl UP UP VDRC-RNAi S E 40531
HSPB8 l(2)efl UP DOWN VDRC-RNAi S E 40531
NFIB NfI UP UP VDRC-RNAi S E 14918
ATP6V1A Vha68-3 DOWN UP VDRC-RNAi S S 34926
ATP6V1A Vha68-3 DOWN UP VDRC-RNAi S S 41646
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Figure 6. Examples of data generated from climbing assays to determine qualitative 
description of modifier status in FL models.  
The following graphs are a sample of the graphical representations of climbing assay data 
used to make the qualitative determinations shown in table 2. The sample depicted shows 
2 suppressors (MDH1 and ITPKA), 2 enhancers (NFIB and ATP2A2), and 2 non-
modifier (PACSIN1 and CACNB4). The x-axis represents the age of the flies in days and 
the y-axis is the mean percentage of flies that climbed to the 9 cm infrared reader from 
the 10 trials of each day’s neurobehavioral test. The top of each graphs denotes the 
human gene symbol, (the Drosophila homolog)- and the class of modifier (RNAi, LOF, 
or OE). 
CNR1 AdoR DOWN DOWN VDRC-RNAi S S 1386
DACH1 dac DOWN DOWN LOF S S 6109
FKBP1B FK506-bp2 DOWN UP VDRC-RNAi S S 45014
FKBP1B FK506-bp2 DOWN UP VDRC-RNAi S S 45015
GRIA3 Glu-RI DOWN DOWN VDRC-RNAi S S 44438
GRIA3 Glu-RI DOWN DOWN VDRC-RNAi S S 108019
ITPKA IP3K2 DOWN DOWN VDRC-RNAi S S 19159
ITPR1 Itp-r83A DOWN DOWN VDRC-RNAi S S 6486
CAP2 capt DOWN DOWN VDRC-RNAi E S 101588
DDR1 Ddr UP UP VDRC-RNAi S S 51719
DPYSL3 CRMP UP DOWN VDRC-RNAi S S 15320
DPYSL3 CRMP UP DOWN LOF S S 24173
DTNA Dyb UP DOWN VDRC-RNAi S S 104485
HSPB8 l(2)efl UP DOWN VDRC-RNAi S S 107305
KCND2 Shal DOWN DOWN VDRC-RNAi E S 103363
LIMK2 LIMK1 UP UP VDRC-RNAi S S 25344
LPP Zyx UP UP VDRC-RNAi S S 21610
MAP4 tau DOWN UP VDRC-RNAi E S 101386
MDH1 Mdh1 DOWN DOWN OE S S 16435
PPP1R16B MYPT-75D DOWN DOWN OE S S 24099
SYNGR3 synaptogyrin DOWN UP VDRC-RNAi E S 100789
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DISCUSSION 
 Over the years, the Botas lab has performed extensive unbiased screens. Through 
these efforts, they have established a normal modifier hit rate in unbiased screens that 
typically falls between 10-15% of tested alleles. The results suggest that the concordance 
of NT and FL modifiers is significantly greater than chance. Of tested NT suppressors, 
41% were also suppressors in the FL model. Meanwhile, only 16% of NT enhancers were 
also enhancers in the FL model, which falls within what is expected in an unbiased 
screen. 
 The sample was significantly enriched with modifiers as compared to the whole 
genome unbiased screening of modifiers that is currently in progress in both NT and FL 
models. While 51% of the NT modifiers also impacted motor performance in the FL 
model, modifiers occasionally had contradictory effects depending on the HD model 
tested. In four instances NT suppressors (PLK2, HSPB1, HSPB8, and NFIB) acted as 
enhancers in the FL model. The same contradictory results appeared four times in NT 
enhancers acting as FL HD suppressors (MAP4, SYNGR3, KCND2, and CAP2). In fact, 
once genotypes that died while aging are removed, as many NT enhancers were 
suppressors as enhancers when tested in the FL model, suggesting there may be less 
overlap among enhancers than suppressors. In a further two instances, NT suppressors 
ROCK2 in the compensatory network and MYST3/KAT in the pathogenic network led to 
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the flies’ death during aging in the FL model. These findings taken together suggest that a 
modifier can have contradictory effects on motor performance depending on the model. 
 These instances of contradictory effects on motor performance depending on the 
model used (FL or NT) could be attributed to the distinct mechanisms of toxicity and 
locations of intracellular aggregation characteristic of NT and FL mutant HTT protein. 
For example, the NT fragment aggregates in both nucleus and cytoplasm at high levels 
and requires protein cleavage, while the FL protein is not cleaved and aggregates 
primarily in the cytoplasm (Warby et al., 2008). Another possible explanation for 
modifiers with contradictory effects could be due to the higher temperature and longer 
duration of the FL experiment relative to the NT screen. These changed variables could 
have increased the potential for secondary toxicity leading to the loss of function of the 
targeted gene. As a result of the significant number of NT modifiers, which showed no 
effect or a contradictory effect in the FL model, this study suggests that future screens 
should test both models independently to gain the clearest picture of the genes involved 
in HD pathogenesis. 
 The experiment has also added further evidence that particular pathogenic and 
compensatory mechanisms are likely shared between both models and are perhaps 
particularly integral to HD progression. The greatest enrichment of shared modifiers, 
encompassing 59% of the modifiers that had the same effect on motor performance in 
both models occurred within the two robust functional gene networks depicted in Figure 
3. Knockdowns of the Drosophila homologs to the human genes ATP6V1A, CALB1, 
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CNR1, FKBP1B, ITPR1, PTBP1, and STXBP1 used in the calcium signaling network 
shown in Figure 3 demonstrated the same modification in both FL and NT models. These 
findings suggest that this compensatory response of decreasing calcium entry into the 
neuron to counter neuronal excitotoxicity is common between HD models. This network 
has also been linked to other effects of early HD progression as excitotoxicity caused by 
high levels of intracellular calcium has been associated with impaired autophagy and 
mitochondrial function, and increased oxidative stress and calpain activity. In this way 
excitotoxicity hinders the key pathway involved in clearing mutant HTT, while 
promoting cellular damage, apoptosis, and mutant HTT cleavage (Imarisio et al., 2008; 
Williams et al., 2008; Zuccato, Valenza, & Cattaneo, 2010). 
 There also appears to be an enrichment in the overlap across models between 
modifiers of the pathogenic network containing genes involved in inflammation and actin 
cytoskeleton regulation. The Drosophila homologs of the human genes LIMK2, PREPL, 
AP1S1, and DPYSL3 involved in the interrelated actin regulation and inflammation 
pathway shown in Figure 3 also shared the same effect on motor performance in both NT 
and FL models. Normal HTT is essential for the cytoskeletal stress response, wherein it 
leaves the ER following increased intracellular calcium levels and translocates to the 
nucleus to participate in actin remodeling. When normal HTT has been reduced or worse 
replaced by mutant HTT, cells exhibit a delayed and inhibited response to stress and 
dysfunctional actin remodeling. This in turn results in synaptic dysfunction, further 
cellular stress and an even higher level of intracellular calcium (Munsie et al., 2011). Also 
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transcriptomic changes associated with HD are linked to the activation of pro-
inflammatory cytokines and chronic inflammation (Möller, 2010; Zuccato, Valenza, & 
Cattaneo, 2010). This inflammation is correlated with impaired autophagy similar to that 
seen in neurons experiencing excitotoxicity.  
 Cytoskeletal regulation, inflammation, and calcium signaling have all been 
strongly correlated with HD progression molecularly and in NT Drosophila models, but 
our research findings help to add evidence of their significance, as they appear to also be 
central to FL HD pathology. Both of these networks seem to modulate autophagy, which 
is seen by some as the key to HD treatment as clearance of mutant HTT, largely by 
autophagy, can lead to disease regression and reversal of neurodegeneration in cell and 
mouse models (Yamamoto, Cremona, & Rothman, 2006). Future studies would be well 
served by seeking out shared mechanisms of promoting autophagy between models as a 
means of clearing HD. Further, we have found that by analyzing these two similarly 
robust networks there does not appear to be significant enrichment in the compensatory 
network as compared to the pathogenic network with each contributing half of the shared 
modifiers. 
Future Directions 
 We are in the process of screening 1000’s more Drosophila genes in an unbiased 
manner through the neurobehavioral climbing assay in the NT model, but a substantial 
majority of the genome remains untested. Further screens will identify new NT modifiers 
that can be re-evaluated in the FL model and add to our understanding of the concordance 
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of modifiers between the models. In the immediate future, 27 confirmed NT modifier 
genotypes where initial amplification of the stock failed will be re-amplified alongside 
the 5 genotypes that were crossed and subsequently died before day 18 of aging, which 
corresponded to the beginning of neurobehavioral testing. The genotypes for which the 
flies died while aging before testing began may reflect enhancers of HD progression, but 
they must be re-tested to confirm whether they are true enhancers or if the experimental 
animals died for a reason unrelated to their HD progression such as infection. This follow 
up experiment will consist of 32 genotypes. Further, 2 genotypes, which were NT 
modifiers where the modification was an X chromosome insertion must be repeated with 
female virgins with FL HD and males with the designated modifier. 
 Our findings have helped confirm the significance of two key functional networks 
to HD progression in the calcium signaling and cytoskeleton regulation and NFKB 
pathways. Shared modifiers identified in both the NT and FL Drosophila models in these 
networks should be further validated in other models such as human cells and mouse 
models or in Drosophila models expressing HD in glial cells instead of or in addition to 
neurons. Building our knowledge of these networks will hopefully help to expand them 
and link them to other processes related to HD pathology. Further, these shared modifiers 
may be promising therapeutic targets and drug screens could be ordered to test the 
feasibility of modulating particular pathways in an effort to slow down the 
neurodegeneration that is a hallmark of HD.  
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 Ultimately, once the complete Drosophila genome has been screened in both NT 
and FL models, a full network analysis can be created. This complete network will be a 
powerful tool in identifying and expanding compensatory and pathogenic genetic 
networks and will be very useful for increasing our understanding of HD. This improved 
understanding will likely uncover more potential therapeutic targets for HD, which 
remains the overarching, long-term goal of unbiased genome wide Drosophila screening. 
!29
REFERENCES 
Al-Ramahi, I., Lu, B., Di Paola, S., Pang, K., Peluso, I., Gallego-Flores, T., … Botas, J.  
 (2016). Functional analysis of transcriptomic alterations in Huntington’s disease.  
 Manuscript submitted for publication. 
Brand, A. H., & Perrimon, N. (1993). Targeted gene expression as a means of altering cell  
 fates and generating dominant phenotypes. Development (Cambridge, England),  
 118(2), 401–415. 
Fennema-Notestine, C., Archibald, S. L., Jacobson, M. W., Corey-Bloom, J., Paulsen, J.  
 S., Peavy, G. M., … Jernigan, T. L. (2004). In vivo evidence of cerebellar atrophy  
 and cerebral white matter loss in Huntington disease. Neurology, 63(6), 989–995. 
Gargano, J. W., Martin, I., Bhandari, P., & Grotewiel, M. S. (2005). Rapid iterative  
 negative geotaxis (RING): a new method for assessing age-related locomotor  
 decline in Drosophila. Experimental Gerontology, 40(5), 386–395. http://doi.org/ 
 10.1016/j.exger.2005.02.005 
Gatchel, J. R., & Zoghbi, H. Y. (2005). Diseases of Unstable Repeat Expansion:  
 Mechanisms and Common Principles. Nature Reviews Genetics, 6(10),  
 743–755. http://doi.org/10.1038/nrg1691 
Graham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., … Hayden, M. R.  
 (2006). Cleavage at the caspase-6 site is required for neuronal dysfunction and  
 degeneration due to mutant huntingtin. Cell, 125(6), 1179–1191. http://doi.org/ 
 10.1016/j.cell.2006.04.026 
Gorter, J. A., Jagadeesh, S., Gahr, C., Boonekamp, J. J., Levine, J. D., & Billeter, J.-C.  
 (2016). The nutritional and hedonic value of food modulate sexual receptivity in  
 Drosophila melanogaster females. Scientific Reports, 6, 19441. http://doi.org/  
 10.1038/srep19441 
Heemskerk, A.-W., & Roos, R. A. C. (2012). Aspiration pneumonia and death in  
 Huntington’s disease. PLoS Currents, 4. http://doi.org/10.1371/currents.RRN1293 
!30
Han, I., You, Y., Kordower, J. H., Brady, S. T., & Morfini, G. A. (2010). Differential  
 vulnerability of neurons in Huntington’s disease: The role of cell type-specific  
 features. Journal of Neurochemistry, 113(5), 1073–1091. http://doi.org/ 
 10.1111/j.1471-4159.2010.06672.x 
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., …  
 Rubinsztein, D. C. (2008). Huntington’s disease: from pathology and genetics to   
 potential therapies. The Biochemical Journal, 412(2), 191–209. http://doi.org/ 
 10.1042/BJ20071619 
Lanska, D. J., Lavine, L., Lanska, M. J., & Schoenberg, B. S. (1988). Huntington’s  
 disease mortality in the United States. Neurology, 38(5), 769–772. 
Lu, B., Al-Ramahi, I., Valencia, A., Wang, Q., Berenshteyn, F., Yang, H., … Palacino, J.  
 (2013). Identification of NUB1 as a suppressor of mutant Huntington toxicity via  
 enhanced protein clearance. Nature Neuroscience, 16(5), 562–570. http://doi.org/  
 10.1038/nn.3367 
Marsh, J. L., Lukacsovich, T., & Thompson, L. M. (2009). Animal models of  
 polyglutamine diseases and therapeutic approaches. The Journal of  
 Biological Chemistry, 284(12), 7431–7435. http://doi.org/10.1074/ 
 jbc.R800065200 
Marsh, J. L., Pallos, J., & Thompson, L. M. (2003). Fly models of Huntington’s disease.  
 Human Molecular Genetics, 12 Spec No 2, R187–193. http://doi.org/10.1093/ 
 hmg/ddg271 
Marsh, J. L., & Thompson, L. M. (2004). Can flies help humans treat  
 neurodegenerative diseases? BioEssays: News and Reviews in Molecular,  
 Cellular and Developmental Biology, 26(5), 485–496. http://doi.org/10.1002/ 
 bies.20029 
Marsh, J. L., Walker, H., Theisen, H., Zhu, Y. Z., Fielder, T., Purcell, J., & Thompson, L.  
 M. (2000). Expanded polyglutamine peptides alone are intrinsically cytotoxic and  
 cause neurodegeneration in Drosophila. Human Molecular Genetics, 9(1), 13– 
 25. 
Möller, T. (2010). Neuroinflammation in Huntington’s disease. Journal of Neural  
 Transmission (Vienna, Austria: 1996), 117(8), 1001–1008. http://doi.org/10.1007/ 
 s00702-010-0430-7 
!31
Munsie, L., Caron, N., Atwal, R. S., Marsden, I., Wild, E. J., Bamburg, J. R., … Truant,  
 R. (2011). Mutant huntingtin causes defective actin remodeling during stress:  
 defining a new role for transglutaminase 2 in neurodegenerative disease. Human  
 Molecular Genetics, 20(10), 1937–1951. http://doi.org/10.1093/hmg/ddr075 
Muqit, M. M. K., & Feany, M. B. (2002). Modelling neurodegenerative diseases in  
 Drosophila: a fruitful approach? Nature Reviews Neuroscience, 3(3), 237–243.  
 http://doi.org/10.1038/nrn751 
Orr, H. T., & Zoghbi, H. Y. (2007). Trinucleotide Repeat Disorders. Annual Review of  
 Neuroscience, 30(1), 575–621. http://doi.org/10.1146/annurev.neuro. 
 29.051605.113042 
Prelich, G. (2012). Gene Overexpression: Uses, Mechanisms, and Interpretation.  
 Genetics, 190(3), 841–854. http://doi.org/10.1534/genetics.111.136911 
Robinow, S., & White, K. (1991). Characterization and spatial distribution of the ELAV  
 protein during Drosophila melanogaster development. Journal of Neurobiology,  
 22(5), 443–461. http://doi.org/10.1002/neu.480220503 
Pandey, U. B., & Nichols, C. D. (2011). Human Disease Models in Drosophila  
 melanogaster and the Role of the Fly in Therapeutic Drug Discovery.   
 Pharmacological Reviews, 63(2), 411–436. http://doi.org/10.1124/pr.110.003293 
Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., & Jette, N. (2012). The  
 incidence and prevalence of Huntington’s disease: A systematic review and meta- 
 analysis. Movement Disorders, 27(9), 1083–1091. http://doi.org/10.1002/mds. 
 25075 
Rawlins, M. (2010). Huntington’s disease out of the closet? The Lancet, 376(9750),  
 1372–1373. http://doi.org/10.1016/S0140-6736(10)60974-9 
Rubinsztein, D. C., & Carmichael, J. (2003). Huntington’s disease: molecular basis of  
 neurodegeneration. Expert Reviews in Molecular Medicine, 5(20), 1–21. http://  
 doi.org/doi:10.1017/S1462399403006549 
!32
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., …  
 Thompson, L. M. (2001). Histone deacetylase inhibitors arrest  
 polyglutamine-dependent neurodegeneration in Drosophila. Nature,  
 413(6857), 739. 
Walker, F. O. (2007). Huntington’s disease. The Lancet, 369(9557), 218–228. http:// 
 doi.org/10.1016/S0140-6736(07)60111-1 
Warby, S. C., Doty, C. N., Graham, R. K., Carroll, J. B., Yang, Y.-Z., Singaraja, R. R., …  
 Hayden, M. R. (2008). Activated caspase-6 and caspase-6-cleaved fragments of  
 huntingtin specifically colocalize in the nucleus. Human Molecular Genetics,  
 17(15), 2390–2404. http://doi.org/10.1093/hmg/ddn139 
Williams, A., Sarkar, S., Cuddon, P., Ttofi, E. K., Saiki, S., Siddiqi, F. H., … Rubinsztein,  
 D. C. (2008). Novel targets for Huntington’s disease in an mTOR-independent  
 autophagy pathway. Nature Chemical Biology, 4(5), 295–305. http://doi.org/ 
 10.1038/nchembio.79 
Yamamoto, A., Cremona, M. L., & Rothman, J. E. (2006). Autophagy-mediated clearance  
 of huntingtin aggregates triggered by the insulin-signaling pathway. The Journal  
 of Cell Biology, 172(5), 719–731. http://doi.org/10.1083/jcb.200510065 
Zaharieva, E., Haussmann, I. U., Bräuer, U., & Soller, M. (2015). Concentration and  
 Localization of Coexpressed ELAV/Hu Proteins Control Specificity of mRNA  
 Processing. Molecular and Cellular Biology, 35(18), 3104–3115. http://doi.org/ 
 10.1128/MCB.00473-15 
Zoghbi, H. Y., & Botas, J. (2002). Mouse and fly models of neurodegeneration.  
 Trends in Genetics, 18(9), 463–471. 
Zuccato, C., Valenza, M., & Cattaneo, E. (2010). Molecular Mechanisms and Potential  
 Therapeutical Targets in Huntington’s Disease. Physiological Reviews, 90(3),  
 905–981. http://doi.org/10.1152/physrev.00041.2009  
!33
CURRICULUM VITAE 
Benjamin Aaron Bleiberg 
Bab42@bu.edu | 713-824-3805 | Birth Year: 1992 
4806 Fern St, Bellaire, TX, 77401 
Education 
Boston University Medical School, Boston, MA: Expected: May 2016 
Master’s In Medical Sciences 
GPA Overall: 3.89/4.0 
MCAT Overall: 521 (99th percentile) 
Duke University, Durham, NC: May 2014 
Bachelor of Science in Psychology, Minors: Biology & Russian Literature in Translation 
GPA Overall: 3.6/ 4.0 Major GPA 4.0/4.0 
Honors: J.A. Morris Undergrad Social Policy Research Fellow (2013), Dean’s List (Fall 
2011) Dean’s List with Distinction (Fall 2013, Spring 2014), National Merit Commended 
Scholar (2010), National Hispanic Scholar (2010), AP Scholar with Distinction (2009) 
Research Experience 
Baylor College of Medicine Neurological Research Institute:  
Botas Lab June 2015-July 2016 
Research Technician 
• Measured behavioral assays of Drosophila models of Huntington’s disease 
• Used an unbiased genetic screen to test the impact of shRNA gene knockdowns 
on Huntington’s disease progression induction or suppression 
Duke Developmental Psychology: Moffitt Lab 
Student Researcher August 2013- May 2014 
• Coded case notes from interviews of 1100 low SES families in London with twins 
from 18 year, ongoing longitudinal study 
• Focused on the relationship between maternal depression and subsequent child 
abuse and neglect data, Graduation with Distinction Thesis 
Duke Social Psychology: Asher Lab  
Practicum Student December 2012-May 2013 
• Created and edited Amazon Mturk study through Qualtrics on gender related 
differences in loneliness and found friendship features were more strongly related 
to friendship satisfaction in women than men 
• Conducted bibliography review of sources and sorted and refined data acquired 
through Mturk 
!34
Texas Children’s Cancer Center: Ahmed Lab, Houston, TX 
Research Assistant May 2012-August 2012 
• Studied adoptive immunotherapy and methods of training immune cells to target 
tumors 
• Developed project creating a GD2/HER2 TanCAR for neuroblastoma and 
osteosarcoma treatment. Tested TanCAR’s effectiveness in functional assays 
• Co-author of poster: Adoptive Immunotherapy Targeting Multiple Antigens in 
Solid Tumors, presented at the 2012 Center for Cell and Gene Therapy Annual 
Symposium in Galveston, TX 
Children’s Nutrition Research Center: Strathearn Lab, Houston, TX 
Project Intern May 2011-August 2011 
• Developed media (audio and pictures) for fMRI scans in studies of mother-infant 
attachment specifically with regard to mothers with a history of drug addiction 
• Contributed to the identification of maternal brain region responses to own      
children’s faces and cries vs. those of an unknown child as a result of addiction 
and assessed the mediating effect of oxytocin on this task 
• Found a difference in mother’s brain activation response to child’s face or cry   
depending on addiction 
Duke Cell Biology: Katsanis Lab: December 2011-May 2012 
Student Researcher 
• Conducted basic experiments in genetics lab focused on the causes and effects of 
genetic diseases, specifically an independent study on the risk factors for 
hereditary hemorrhagic telangiectasia in the endoglin gene 
• Lab work included replicating patient DNA in bacteria, running bacterial DNA 
through gel electrophoresis, analyzing gel plates, and implanting bacterial DNA in 
zebra fish models 
Leadership Experience 
Duke Library Undergraduate Advisory Board Member: September 2013-May 2014 
• Participated in advisory committee tasked with ensuring library resources are best 
utilized and widely accessible to the benefit of Duke’s scholarly community 
!35
Duke Presidential Campus Sustainability & Transportation Committees 
Student Government Representative August 2012-May 2014 
• Participated in an advisory committee of administrators, faculty, and students 
tasked with sending recommendations for Duke sustainability and transportation 
efforts to the Office of the President 
• Met with committees to advance Duke’s Transportation goals and Carbon 
Neutrality Initiative, including the conversion of Duke’s coal fired power plant to 
natural gas 
Maxwell House: January 2011-May 2014 
Social and Philanthropy Chair (Fall 2012 & Fall 2013) 
• A diverse community, that provides service and social programming for 
undergraduates 
• Led group programming and helped integrate new members by structuring        
orientation and social events  
• collaborating with other executives to balance the budget and act as a liaison 
between Maxwell House and Duke administration 
Duke STARS (Students Taking An Active Role in Sustainability)  
Executive Board Member August 2012-August 2013 
• Part of a small team of undergraduate and graduate students actively searching for 
and implementing methods to make Duke University more sustainable with an 
annual budget of $25,000 to fund sustainability projects designed by the 
committee and the Duke community at large 
Habitat for Humanity: August 2010-May 2011 
• Ongoing work on building projects and raising awareness and funds for  
homelessness 
• Involvement culminated in alternative spring break trip to El Paso, Texas to build 
new homes for the homeless and refurbish older homes built by past habitat 
groups 
Skills 
Software Experience: LoggerPro, MS Office Suite (Word, Excel, PowerPoint, etc.), Mac 
OS X, Windows 7, Adobe Photoshop, Praat Audio Editing, Cog Lab 2.0, SPSS, Qualtrics 
Laboratory Experience: Gel Electrophoresis and analysis, Aseptic Technique, Tissue 
Culture, work with radioactive and bio-hazardous material, Plasmid Preparation 
Languages: Intermediate Spanish
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